VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
1022
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
184
Interactions with Platform & by Email
PARTICIPANTS
41
Unique # Participated
VALIDATIONS
18
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JAN 2021
TABLES
144
PAGES
402
EDITION
7
PRICE
USD $5450
The World of Viral Vector Manufacturing is Changing Fast!
It's Time to Identify Upcoming Revenue Pockets & Growth Areas.
Amid the COVID-19 crisis, the global market for Viral Vector Manufacturing estimated at US$450.5 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 18.5% over the analysis period 2020-2027.Retroviral Vectors, one of the segments analyzed in the report, is projected to grow at a 18.5% CAGR to reach US$547.1 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adenoviral Vectors segment is readjusted to a revised 18.8% CAGR for the next 7-year period. This segment currently accounts for a 25.3% share of the global Viral Vector Manufacturing market.
The Viral Vector Manufacturing market in the U.S. is estimated at US$265.6 Million in the year 2020. The country currently accounts for a 58.95% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$58 Million in the year 2027 trailing a CAGR of 21.9% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.8% and 16% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR while Rest of European market (as defined in the study) will reach US$58 Million by the year 2027.
In the global Adeno-associated Viral Vectors segment, USA, Canada, Japan, China and Europe will drive the 19.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$89.5 Million in the year 2020 will reach a projected size of US$316.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$37.7 Million by the year 2027.We bring years of research experience to this 7th edition of our report. The 229-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Batavia Biosciences B.V.;
BioNTech IMFS GmbH;
Cobra Biologics Ltd.;
FinVector Oy;
FUJIFILM Diosynth Biotechnologies;
Genelux Corporation;
Kaneka Eurogentec S.A.;
Lonza Group AG;
MaxCyte, Inc.;
Merck KGaA;
Novasep Inc.;
Oxford BioMedica plc;
Sirion-Biotech GmbH;
Spark Therapeutics, Inc.;
Thermo Fisher Scientific Inc.;
Vector Biolabs;
Vigene Biosciences, Inc.;
Virovek, Inc.
» Type (Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors, Other Types) » Disease (Cancer, Genetic Disorders, Infectious Diseases, Other Diseases) » End-Use (Pharma & Biopharma Companies, Research Institutes)
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Rest of Europe » Asia-Pacific » Rest of World
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Impact of COVID-19 Pandemic and Looming Global Recession |
| With Viral Vector-based Vaccines Used for COVID-19 in Development, Viral Vector Manufacturing Market Poised to Benefit |
| An Introduction to Viral Vector Manufacturing |
| Applications of Viral Vectors |
| Types of Viral Vectors |
| Global Viral Vector Manufacturing Market: Prospects & Outlook |
| Competition |
| COVID-19 Pandemic Puts Pressure on Already Constrained Viral Vector Manufacturing Capacity |
| A Glance at Select Investments in Expanding Viral Vector Manufacturing Capacity |
| Recent Market Activity |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Increasing Prevalence of Infectious Diseases, Genetic Disorders & Cancers Drives Market |
| EXHIBIT: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 |
| EXHIBIT: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030 |
| EXHIBIT: Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-2025) & (2045-2050) |
| Gene Therapy Emerges as a Major Therapeutic Approach for Inheritable and Acquired Diseases, Spurring Market Prospects |
| Gene Therapy Set to Witness Rapid Growth Post COVID-19 |
| Viral Vectors Lead the Gene Therapy Market |
| Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy |
| Lentiviral Vectors Witness Increased Interest for Gene Therapy |
| Funding Support for Gene Therapy Development Presents Market Opportunities |
| Complexity in Viral Vector Production for Gene therapies |
| Amidst Rising Cancer Incidence, Focus on Viral Vector-based Gene Therapies to Boost Market |
| EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 |
| EXHIBIT: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018 |
| EXHIBIT: Number of New Cancer Cases and Deaths (in Million) by Region for 2018 |
| Engineered and Natural Oncolytic Viral Vectors: A Key Development in Viral Vector-based Cancer Therapy |
| Growing Threat Posed by Infectious Diseases Drives Focus onto Vector Viral-based Therapies & Vaccines |
| EXHIBIT: Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %) |
| EXHIBIT: Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %) |
| Rising Significance of Viral Vectors in New Vaccine Development |
| Adenovirus-based Vaccines: Evolution Over the Years |
| Viral Vector Emerges as a Next-Gen Platform for COVID-19 Vaccines Development |
| Rush to Develop and Rollout COVID-19 Vaccines Boosts Prospects for Viral Vector Manufacturing |
| EXHIBIT: COVID-19 Vaccines Under Development |
| EXHIBIT: Vaccines in Pipeline by Technology |
| EXHIBIT: Vaccine Technologies in Pre-Clinical Studies |
| Replicating and Non-Replicating Viral Vector-Based Vaccines |
| EXHIBIT: Non-Replicating Viral vector Vaccine in Clinical Development: As on December 2nd, 2020 |
| EXHIBIT: Replicating Viral vector Vaccine Candidate in Clinical Development: As on December 2nd, 2020 |
| Adenoviral Vectors: Frontrunners of New Vaccine for COVID-19 |
| Vaccines for COVID-19 Confronts Logistic Obstacles to Overcome |
| Market to Benefit from the Emergence of New Technologies to Manufacture Viral Vectors |
| New Trends for Optimizing Workflow Using Viral Vectors |
| Production Workflow & Viral Vectors |
| Closed-System-Adherent Culture of Cells: Recent Advances |
| Limitations in Viral Vector Manufacturing Impact Market |
| Innovations & Collaborations: Essential to Resolve Challenges Facing Large-Scale GMP Viral Vector Manufacturing |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Retroviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Adenoviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Adeno-associated Viral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| World Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| World 11-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| USA Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| USA 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| USA Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| USA Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| USA 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| USA Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| USA Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| USA 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Canada Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Canada 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| Canada Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Canada Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Canada 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| Canada Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Canada Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Canada 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Japan Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Japan 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| Japan Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Japan Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Japan 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| Japan Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Japan Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Japan 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| China Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| China 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| China Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| China Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| China 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| China Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| China Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| China 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 |
| Europe Historic Review for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Europe 11-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2020 & 2027 |
| Europe Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Europe 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| Europe Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Europe 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| Europe Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Europe 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| France Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| France 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| France Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| France Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| France 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| France Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| France Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| France 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Germany Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Germany 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| Germany Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Germany Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Germany 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| Germany Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Germany Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Germany 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Italy Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Italy 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| Italy Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Italy Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Italy 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| Italy Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Italy Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Italy 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| UK Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| UK 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| UK Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| UK Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| UK 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| UK Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| UK Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| UK 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Rest of Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Rest of Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Rest of Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Rest of Europe 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Asia-Pacific Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Asia-Pacific Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Asia-Pacific Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Asia-Pacific 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Rest of World Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Rest of World 11-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2020 & 2027 |
| Rest of World Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Rest of World Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Rest of World 11-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2020 & 2027 |
| Rest of World Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 |
| Rest of World Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 |
| Rest of World 11-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled : 77 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com